XML 38 R25.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Segment and Geographic Information | 3 Months Ended
--- | ---
Dec. 31, 2023
Segment Reporting [Abstract] |
Segment and Geographic Information | 15. Segment and Geographic Information Operating segments are defined as components of an enterprise that engage in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker (“CODM”) in deciding how to allocate resources and to assess performance. The Company’s Chief Executive Officer is the Company’s chief operating decision maker. As previously announced, effective October 1, 2023, the Company realigned its organizational structure to three principal business segments to enhance its commercial strategy for accelerating growth and to enable additional profitability initiatives. These segments align with changes in how the Company’s chief operating decision maker manages the business, allocates resources, and assesses performance. The Company’s operating and reportable segments consist of the following:
| ● | Sample Management Solutions (“SMS”). Sample Management Solutions operates as a single business unit offering end-to-end sample management products and services, including: Sample & Repository Services and Core Products (Automated Stores, Cryogenic Systems, Automated Sample Tube, and Consumables and Instruments).
| ● | Multiomics. The Multiomics business resources operate under a single business unit that provides genomic and other sample analysis services, including gene sequencing and gene synthesis.
| ● | B Medical Systems. B Medical Systems business resources operate as a single business unit focused on the manufacturing and distribution of temperature-controlled storage and transportation solutions in international markets to governments, health institutions, and non-government organizations.
​ The segment realignment had no impact on the Company’s consolidated financial position, results of operations, or cash flows. All segment information is reflective of this new structure, and prior period information has been recast to conform to our current period presentation. Management considers adjusted operating income, which excludes charges related to amortization of intangible assets, purchase accounting impact on inventory, restructuring charges, merger and acquisition costs and costs related to share repurchase, governance-related matters, and other unallocated corporate expenses, as the primary performance metric when evaluating the segments’ operations. The following is the summary of the financial information for the Company’s reportable segments for the three months ended December 31, 2023 and 2022 (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | Three Months Ended December 31,
​ | ​ | ​ | 2023 | ​ | 2022
Revenue: |  | ​ | ​ | ​ | ​ | ​ |
Sample Management Solutions | ​ | ​ | $ | 79,005 | ​ | $ | 75,455
Multiomics | ​ | ​ |  | 62,720 | ​ |  | 61,089
B Medical Systems | ​ | ​ | ​ | 12,592 | ​ | ​ | 41,822
Total revenue | ​ | ​ | $ | 154,317 | ​ | $ | 178,366
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Adjusted operating (loss) income: | ​ | ​ |  | ​ | ​ |  | ​
Sample Management Solutions | ​ | ​ | $ | (856) | ​ | $ | (2,998)
Multiomics | ​ | ​ |  | (3,451) | ​ |  | (3,265)
B Medical Systems | ​ | ​ | ​ | (4,409) | ​ | ​ | 6,303
Segment adjusted operating (loss) income | ​ | ​ | ​ | (8,716) | ​ | ​ | 40
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amortization of completed technology | ​ | ​ | ​ | 5,627 | ​ | ​ | 4,168
Purchase accounting impact on inventory | ​ | ​ | ​ | — | ​ | ​ | 2,869
Amortization of intangible assets other than completed technology | ​ | ​ | ​ | 6,862 | ​ | ​ | 7,372
Restructuring charges | ​ | ​ | ​ | 1,120 | ​ | ​ | 1,461
Merger and acquisition costs and costs related to share repurchase(1) | ​ | ​ | ​ | 4,321 | ​ | ​ | 11,838
Other unallocated corporate expenses | ​ | ​ | ​ | 31 | ​ | ​ | 17
Total operating loss | ​ | ​ | ​ | (26,677) | ​ | ​ | (27,685)
Interest income, net | ​ | ​ | ​ | 10,081 | ​ | ​ | 10,665
Other, net | ​ | ​ | ​ | 682 | ​ | ​ | 1,145
Loss before income taxes | ​ | ​ | $ | (15,914) | ​ | $ | (15,875)
(1) Includes expenses related to governance-related matters. | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ The Company has corrected the segment adjusted operating (loss) income for the three-month period ended December 31, 2022 as certain corporate expenses that are not part of the Company’s CODM’s review of operating segment performance were improperly included in the previously disclosed segment adjusted operating (loss) income. The previously disclosed amount of total segment adjusted operating (loss) income for the reportable segments was understated by $8.5 million. The total net loss before income taxes remained unchanged. ​ The following is the summary of the asset information for the Company’s reportable segments for the three months ended December 31, 2023 and 2022 (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Assets: | ​ | ​ | December 31, 2023 | ​ | September 30, 2023
Sample Management Solutions | ​ | ​ | $ | 874,037 | ​ | $ | 675,708
Multiomics | ​ | ​ | ​ | 490,898 | ​ | ​ | 534,437
B Medical Systems | ​ | ​ | ​ | 376,613 | ​ | ​ | 511,640
Total assets | ​ | ​ | $ | 1,741,548 | ​ | $ | 1,721,785
​ The following is a reconciliation of the segment assets to the corresponding amounts presented in the Condensed Consolidated Balance Sheets as of December 31, 2023 and September 30, 2023 (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | December 31, |  | September 30,
​ | ​ | 2023 | ​ | 2023
Segment assets |  | $ | 1,741,548 |  | $ | 1,721,785
Cash and cash equivalents, restricted cash, and marketable securities | ​ |  | 1,051,395 | ​ |  | 1,134,256
Deferred tax assets | ​ |  | 1,341 | ​ |  | 571
Other assets | ​ | ​ | 30,030 | ​ | ​ | 29,108
Total assets | ​ | $ | 2,824,314 | ​ | $ | 2,885,720
​ Revenue from external customers is attributed to geographic areas based on locations in which the product is shipped. Net revenue by geographic area for the three months ended December 31, 2023 and 2022 are as follows (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended December 31,
​ |  | 2023 | ​ | 2022
Geographic Location: | ​ | ​ | ​ | ​ | ​ | ​
United States | ​ | $ | 90,592 | ​ | $ | 87,717
Africa | ​ | ​ | 7,511 | ​ | ​ | 17,210
China | ​ | ​ | 14,898 | ​ | ​ | 13,408
United Kingdom | ​ | ​ | 5,699 | ​ | ​ | 5,413
Rest of Europe | ​ | ​ | 24,832 | ​ | ​ | 39,422
Asia Pacific/Other | ​ | ​ | 10,785 | ​ | ​ | 15,196
Total revenue | ​ | $ | 154,317 | ​ | $ | 178,366
​ The Company had no individual customer that accounted for 10% or more of its consolidated revenue or accounts receivable for the three months ended December 31, 2023. The Company had one individual customer that accounted for 10% or more of its consolidated revenue and accounts receivable for the three months ended December 31, 2022. This individual customer is a distributor shipping to end users in 17 countries. This customer accounted for 20% and 12% of revenue and accounts receivable, respectively, during and as of the three months ended December 31, 2022.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//280/tableOfContent Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration